RU2011123655A - Полностью гуманизированные антитела против n-кадгерина - Google Patents
Полностью гуманизированные антитела против n-кадгерина Download PDFInfo
- Publication number
- RU2011123655A RU2011123655A RU2011123655/10A RU2011123655A RU2011123655A RU 2011123655 A RU2011123655 A RU 2011123655A RU 2011123655/10 A RU2011123655/10 A RU 2011123655/10A RU 2011123655 A RU2011123655 A RU 2011123655A RU 2011123655 A RU2011123655 A RU 2011123655A
- Authority
- RU
- Russia
- Prior art keywords
- cancer
- antibody
- cadherin
- fragment
- tissue sample
- Prior art date
Links
- 206010028980 Neoplasm Diseases 0.000 claims abstract 30
- 201000011510 cancer Diseases 0.000 claims abstract 30
- 238000000034 method Methods 0.000 claims abstract 23
- 102000000905 Cadherin Human genes 0.000 claims abstract 20
- 108050007957 Cadherin Proteins 0.000 claims abstract 20
- 108050000637 N-cadherin Proteins 0.000 claims abstract 20
- 210000001519 tissue Anatomy 0.000 claims abstract 15
- 239000012634 fragment Substances 0.000 claims abstract 13
- 125000003275 alpha amino acid group Chemical group 0.000 claims abstract 4
- 206010005003 Bladder cancer Diseases 0.000 claims abstract 3
- 206010060862 Prostate cancer Diseases 0.000 claims abstract 3
- 208000000236 Prostatic Neoplasms Diseases 0.000 claims abstract 3
- 208000007097 Urinary Bladder Neoplasms Diseases 0.000 claims abstract 3
- 210000005068 bladder tissue Anatomy 0.000 claims abstract 3
- 210000002307 prostate Anatomy 0.000 claims abstract 3
- 201000005112 urinary bladder cancer Diseases 0.000 claims abstract 3
- FWMNVWWHGCHHJJ-SKKKGAJSSA-N 4-amino-1-[(2r)-6-amino-2-[[(2r)-2-[[(2r)-2-[[(2r)-2-amino-3-phenylpropanoyl]amino]-3-phenylpropanoyl]amino]-4-methylpentanoyl]amino]hexanoyl]piperidine-4-carboxylic acid Chemical compound C([C@H](C(=O)N[C@H](CC(C)C)C(=O)N[C@H](CCCCN)C(=O)N1CCC(N)(CC1)C(O)=O)NC(=O)[C@H](N)CC=1C=CC=CC=1)C1=CC=CC=C1 FWMNVWWHGCHHJJ-SKKKGAJSSA-N 0.000 claims abstract 2
- 210000000130 stem cell Anatomy 0.000 claims 4
- 210000004027 cell Anatomy 0.000 claims 3
- 208000018821 hormone-resistant prostate carcinoma Diseases 0.000 claims 3
- 208000037819 metastatic cancer Diseases 0.000 claims 2
- 208000011575 metastatic malignant neoplasm Diseases 0.000 claims 2
- 102000039446 nucleic acids Human genes 0.000 claims 2
- 108020004707 nucleic acids Proteins 0.000 claims 2
- 150000007523 nucleic acids Chemical class 0.000 claims 2
- 239000002773 nucleotide Substances 0.000 claims 1
- 125000003729 nucleotide group Chemical group 0.000 claims 1
- 239000000523 sample Substances 0.000 abstract 3
- 239000013068 control sample Substances 0.000 abstract 1
- 239000005556 hormone Substances 0.000 abstract 1
- 229940088597 hormone Drugs 0.000 abstract 1
- 208000016691 refractory malignant neoplasm Diseases 0.000 abstract 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
- A61K39/39533—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals
- A61K39/3955—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals against proteinaceous materials, e.g. enzymes, hormones, lymphokines
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
- A61P35/04—Antineoplastic agents specific for metastasis
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
- C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
- C07K16/2896—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against molecules with a "CD"-designation, not provided for elsewhere
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
- C12N15/09—Recombinant DNA-technology
- C12N15/11—DNA or RNA fragments; Modified forms thereof; Non-coding nucleic acids having a biological activity
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
- G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
- G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
- G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
- G01N33/574—Immunoassay; Biospecific binding assay; Materials therefor for cancer
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
- G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
- G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
- G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
- G01N33/574—Immunoassay; Biospecific binding assay; Materials therefor for cancer
- G01N33/57407—Specifically defined cancers
- G01N33/57434—Specifically defined cancers of prostate
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
- G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
- G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
- G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
- G01N33/574—Immunoassay; Biospecific binding assay; Materials therefor for cancer
- G01N33/57484—Immunoassay; Biospecific binding assay; Materials therefor for cancer involving compounds serving as markers for tumor, cancer, neoplasia, e.g. cellular determinants, receptors, heat shock/stress proteins, A-protein, oligosaccharides, metabolites
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
- C07K2317/21—Immunoglobulins specific features characterized by taxonomic origin from primates, e.g. man
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/60—Immunoglobulins specific features characterized by non-natural combinations of immunoglobulin fragments
- C07K2317/62—Immunoglobulins specific features characterized by non-natural combinations of immunoglobulin fragments comprising only variable region components
- C07K2317/622—Single chain antibody (scFv)
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N2333/00—Assays involving biological materials from specific organisms or of a specific nature
- G01N2333/435—Assays involving biological materials from specific organisms or of a specific nature from animals; from humans
- G01N2333/705—Assays involving receptors, cell surface antigens or cell surface determinants
- G01N2333/70503—Immunoglobulin superfamily, e.g. VCAMs, PECAM, LFA-3
- G01N2333/70525—ICAM molecules, e.g. CD50, CD54, CD102
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Immunology (AREA)
- Engineering & Computer Science (AREA)
- Molecular Biology (AREA)
- Medicinal Chemistry (AREA)
- Biomedical Technology (AREA)
- General Health & Medical Sciences (AREA)
- Urology & Nephrology (AREA)
- Hematology (AREA)
- Organic Chemistry (AREA)
- Biochemistry (AREA)
- Microbiology (AREA)
- Biotechnology (AREA)
- Cell Biology (AREA)
- Genetics & Genomics (AREA)
- Physics & Mathematics (AREA)
- Oncology (AREA)
- Food Science & Technology (AREA)
- Pathology (AREA)
- Analytical Chemistry (AREA)
- General Physics & Mathematics (AREA)
- Hospice & Palliative Care (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- Animal Behavior & Ethology (AREA)
- Pharmacology & Pharmacy (AREA)
- Biophysics (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Epidemiology (AREA)
- Mycology (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Zoology (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Engineering & Computer Science (AREA)
- Wood Science & Technology (AREA)
- Endocrinology (AREA)
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US11304208P | 2008-11-10 | 2008-11-10 | |
| US61/113,042 | 2008-11-10 | ||
| PCT/US2009/063881 WO2010054377A2 (en) | 2008-11-10 | 2009-11-10 | Fully human antibodies against n-cadherin |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| RU2011123655A true RU2011123655A (ru) | 2012-12-20 |
Family
ID=42153647
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| RU2011123655/10A RU2011123655A (ru) | 2008-11-10 | 2009-11-10 | Полностью гуманизированные антитела против n-кадгерина |
Country Status (13)
| Country | Link |
|---|---|
| US (2) | US8703920B2 (enExample) |
| EP (1) | EP2356145A4 (enExample) |
| JP (1) | JP2012508027A (enExample) |
| KR (1) | KR20110084309A (enExample) |
| CN (1) | CN102300873A (enExample) |
| AU (1) | AU2009313239A1 (enExample) |
| BR (1) | BRPI0921457A2 (enExample) |
| CA (1) | CA2743122A1 (enExample) |
| CO (1) | CO6362022A2 (enExample) |
| IL (1) | IL212795A0 (enExample) |
| MX (1) | MX2011004945A (enExample) |
| RU (1) | RU2011123655A (enExample) |
| WO (1) | WO2010054377A2 (enExample) |
Families Citing this family (9)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US8663635B2 (en) * | 2006-03-21 | 2014-03-04 | The Regents Of The University Of California | N-cadherin: target for cancer diagnosis and therapy |
| WO2007109347A2 (en) * | 2006-03-21 | 2007-09-27 | The Regents Of The University Of California | N-cadherin and ly6 e: targets for cancer diagnosis and therapy |
| EA201001603A1 (ru) * | 2008-04-04 | 2011-06-30 | Те Риджентс Оф Те Юниверсити Оф Калифорния | Антитела против кадгерина, блокирующие рост опухоли, ангиогенез и метастазирование |
| US8703920B2 (en) | 2008-11-10 | 2014-04-22 | The Regents Of The University Of California | Fully human antibodies against N-cadherin |
| GB201119089D0 (en) | 2011-11-04 | 2011-12-21 | Isis Innovation | Treatment of musculoskeletal fibroproliferative disorders |
| EP2830659A1 (en) | 2012-03-27 | 2015-02-04 | Novartis AG | Treatment of fibrosis |
| WO2016028663A1 (en) * | 2014-08-21 | 2016-02-25 | Johnson Controls Technology Company | Battery monitoring system |
| WO2018226795A1 (en) * | 2017-06-06 | 2018-12-13 | The Regents Of The University Of California | Humanized anti-n-cadherin antibodies and uses thereof |
| US20240239885A1 (en) * | 2021-05-13 | 2024-07-18 | WuXi Biologics Ireland Limited | Antibody conjugate comprising anti-p-cadherin antibody and uses thereof |
Family Cites Families (14)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US5889157A (en) | 1990-10-12 | 1999-03-30 | The United States Of America As Represented By The Department Of Health And Human Services | Humanized B3 antibody fragments, fusion proteins, and uses thereof |
| AU669124B2 (en) | 1991-09-18 | 1996-05-30 | Kyowa Hakko Kirin Co., Ltd. | Process for producing humanized chimera antibody |
| US6680175B2 (en) | 1998-05-05 | 2004-01-20 | Adherex Technologies, Inc. | Methods for diagnosing and evaluating cancer |
| US6277824B1 (en) | 1998-07-10 | 2001-08-21 | Adherex Technologies | Compounds and methods for modulating adhesion molecule function |
| AU2001249064A1 (en) | 2000-02-22 | 2001-09-03 | Mount Sinai School Of Medicine Of New York University | N-cadherin modulated migration, invasion, and metastasis |
| US20030190602A1 (en) | 2001-03-12 | 2003-10-09 | Monogen, Inc. | Cell-based detection and differentiation of disease states |
| CA2523716C (en) * | 2003-05-31 | 2014-11-25 | Micromet Ag | Human anti-human cd3 binding molecules |
| WO2005097184A2 (en) * | 2004-03-26 | 2005-10-20 | Human Genome Sciences, Inc. | Antibodies against nogo receptor |
| WO2006138275A2 (en) | 2005-06-13 | 2006-12-28 | The Regents Of The University Of Michigan | Compositions and methods for treating and diagnosing cancer |
| WO2007109347A2 (en) | 2006-03-21 | 2007-09-27 | The Regents Of The University Of California | N-cadherin and ly6 e: targets for cancer diagnosis and therapy |
| US20100278821A1 (en) | 2006-03-21 | 2010-11-04 | The Regents Of The University Of California | N-cadherin: target for cancer diagnosis and therapy |
| US8663635B2 (en) | 2006-03-21 | 2014-03-04 | The Regents Of The University Of California | N-cadherin: target for cancer diagnosis and therapy |
| EA201001603A1 (ru) | 2008-04-04 | 2011-06-30 | Те Риджентс Оф Те Юниверсити Оф Калифорния | Антитела против кадгерина, блокирующие рост опухоли, ангиогенез и метастазирование |
| US8703920B2 (en) | 2008-11-10 | 2014-04-22 | The Regents Of The University Of California | Fully human antibodies against N-cadherin |
-
2009
- 2009-11-09 US US12/590,601 patent/US8703920B2/en not_active Expired - Fee Related
- 2009-11-10 WO PCT/US2009/063881 patent/WO2010054377A2/en not_active Ceased
- 2009-11-10 EP EP09825592A patent/EP2356145A4/en not_active Withdrawn
- 2009-11-10 JP JP2011535765A patent/JP2012508027A/ja active Pending
- 2009-11-10 CN CN2009801544698A patent/CN102300873A/zh active Pending
- 2009-11-10 RU RU2011123655/10A patent/RU2011123655A/ru unknown
- 2009-11-10 CA CA2743122A patent/CA2743122A1/en not_active Abandoned
- 2009-11-10 BR BRPI0921457A patent/BRPI0921457A2/pt not_active Application Discontinuation
- 2009-11-10 AU AU2009313239A patent/AU2009313239A1/en not_active Abandoned
- 2009-11-10 MX MX2011004945A patent/MX2011004945A/es unknown
- 2009-11-10 KR KR1020117013339A patent/KR20110084309A/ko not_active Withdrawn
-
2011
- 2011-05-09 IL IL212795A patent/IL212795A0/en unknown
- 2011-06-08 CO CO11070983A patent/CO6362022A2/es not_active Application Discontinuation
-
2013
- 2013-06-17 US US13/919,652 patent/US20140017240A1/en not_active Abandoned
Also Published As
| Publication number | Publication date |
|---|---|
| CA2743122A1 (en) | 2010-05-14 |
| EP2356145A4 (en) | 2012-07-18 |
| WO2010054377A9 (en) | 2011-02-03 |
| EP2356145A2 (en) | 2011-08-17 |
| MX2011004945A (es) | 2011-11-01 |
| US20140017240A1 (en) | 2014-01-16 |
| JP2012508027A (ja) | 2012-04-05 |
| US8703920B2 (en) | 2014-04-22 |
| CO6362022A2 (es) | 2012-01-20 |
| WO2010054377A3 (en) | 2010-09-16 |
| IL212795A0 (en) | 2011-07-31 |
| WO2010054377A2 (en) | 2010-05-14 |
| US20100233170A1 (en) | 2010-09-16 |
| AU2009313239A1 (en) | 2011-07-07 |
| KR20110084309A (ko) | 2011-07-21 |
| CN102300873A (zh) | 2011-12-28 |
| BRPI0921457A2 (pt) | 2016-01-12 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| RU2011123655A (ru) | Полностью гуманизированные антитела против n-кадгерина | |
| Hemmerlein et al. | Overexpression of Eag1 potassium channels in clinical tumours | |
| CN109206514B (zh) | Tslp单克隆抗体及其制备方法和应用 | |
| JP2022028918A5 (enExample) | ||
| US9823251B2 (en) | Anti-Uroplakin II antibodies systems and methods | |
| JP2017518366A5 (enExample) | ||
| WO2014036495A4 (en) | Diagnostic assays and kits for detection of folate receptor 1 | |
| EP3052522B1 (en) | Anti-sox10 antibody systems and methods | |
| HRP20110171T1 (hr) | Postupak za predviđanje reakcije na liječenje inhibitorom her dimerizacije | |
| RU2014108048A (ru) | Способ обнаружения рака поджелудочной железы | |
| RU2013142334A (ru) | КОМПОЗИЦИИ И СПОСОБЫ ПРИМЕНЕНИЯ ДЛЯ ОПРЕДЕЛЕНИЯ НЕ4а | |
| RS55539B1 (sr) | Antitelo koje prepoznaje humani inhibitorni faktor leukemije (lif) i primena anti-lif antitela u lečenju bolesti povezanih sa neželjenom proliferacijom ćelija | |
| KR20110090985A (ko) | 인간 ｃｘｃｌ１ 단백질의 면역학적 측정 방법 | |
| RU2013104137A (ru) | Изоформы bard1 при раке легкого и колоректальном раке и их применение | |
| RU2019110953A (ru) | Моноклональное антитело, специфически связывающееся с тиоредоксином-1, и его применение | |
| CN116410322A (zh) | 抗人pcdh7蛋白的单克隆抗体及其应用 | |
| US8257716B2 (en) | Anti-PDEF antibodies and uses thereof | |
| CN101302254A (zh) | 抗肝癌源性生长因子单克隆抗体及其应用 | |
| AU2011298090A1 (en) | Antibody against colorectal cancer marker | |
| JP2018520366A5 (enExample) | ||
| CN116789835A (zh) | 抗Trop2蛋白的单克隆抗体及其应用 | |
| US20090175871A1 (en) | Method for demonstrating presence or absence of markers associated with the presence and/or the chemosensitivity of tumors | |
| DK1541676T3 (da) | Mod prothrombin-fragment F1 2 rettede abtistoffer, deres fremstilling og anvendelse | |
| CN117624353B (zh) | 结合平滑肌肌球蛋白重链的抗体及其用途 | |
| KR102688094B1 (ko) | Cobll1 단백질 특이 항체 또는 이의 항원 결합 단편, 및 이의 용도 |